Cellebrite DI .(US:CLBT)2025-02-13 12:15Financial Performance - Fourth-quarter 2024 revenue reached $109.0 million, a 17% year-over-year increase[1] - Subscription revenue for the fourth quarter was $95.1 million, up 21% year-over-year[3] - Annual Recurring Revenue (ARR) grew 25% to $395.9 million[1] - Full-year 2024 revenue totaled $401.2 million, reflecting a 23% year-over-year increase[8] - Revenue for Q4 2024 reached $109,049,000, a 17.2% increase from $93,013,000 in Q4 2023[27] - Total revenue for Q4 2024 reached $109.049 million, a 17.2% increase from $93.013 million in Q4 2023[31] Profitability Metrics - Adjusted EBITDA for the fourth quarter was $28.8 million, with a margin of 26.4%[3] - Operating income for Q4 2024 was $15,727,000, compared to $14,999,000 in Q4 2023, indicating a 4.9% increase[27] - Net income for Q4 2024 was $19,269,000, a significant recovery from a net loss of $14,647,000 in Q4 2023[27] - The adjusted EBITDA margin for the year ended December 31, 2024, was 24.8%, compared to 19.1% in 2023, showing an improvement of 5.7 percentage points[27] - The company achieved a non-GAAP operating income of $92,119 million for the year 2024, compared to $55,282 million in 2023, indicating a 67% increase[36] - The non-GAAP net income for the year 2024 reached $97,761 million, up from $60,926 million in 2023, which is a 60% increase[38] Cash Flow and Assets - Cash flow from operating activities for the year ended December 31, 2024, was $132,171,000, compared to $102,058,000 in 2023, marking a 29.5% increase[27] - Total assets as of December 31, 2024, amounted to $690,567,000, up from $532,885,000 in 2023, representing a 29.6% growth[28] - The company ended the year with cash and cash equivalents of $191.659 million, stable compared to $189.517 million at the end of 2023[33] Expenses and Investments - Research and development expenses for the year were $98.415 million, a 16.7% increase from $84.386 million in 2023, reflecting ongoing investment in new technologies[31] - Total operating expenses for the year were $281.704 million, up from $238.642 million in 2023, primarily driven by increased R&D and marketing efforts[31] - Share-based compensation for the year 2024 totaled $30,575 million, up from $18,998 million in 2023, representing a 61% increase[38] Future Outlook - For 2025, the company expects ARR between $480 million and $495 million, representing annual growth of 21% to 25%[10] - The first-quarter 2025 revenue expectation is between $107 million and $112 million, with annual growth projected at 19% to 25%[10] - Cellebrite's outlook for 2025 includes plans to advance its market and technology leadership while generating robust free cash flow[26] Product and Technology Developments - Cellebrite's Government Cloud platform received FedRAMP High Ready designation, enhancing its cloud security offerings[7] - Generative Artificial Intelligence capabilities were launched within the Guardian evidence management solution[12] Deferred Revenue - The company reported an increase in deferred revenue of $22.317 million for the year, indicating strong future revenue potential[33]